Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: Rapid profound reduction in involved FLC predicts achievement of VGPR

European Journal of Haematology

Volumn 93, Issue 5, 2014, Pages 407-413

  Hansen, Charlotte T ^a   Pedersen, Per T ^b   Nielsen, Lars C ^b   Abildgaard, Niels ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b ESBJERG HOSPITAL   (Denmark)

Author keywords

Half life; Immunoglobulin light chains; Multiple myeloma; Treatment outcome

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; M PROTEIN; MELPHALAN; PREDNISONE; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; MULTIPLE MYELOMA M-PROTEINS; PARAPROTEIN; PYRAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; FEMALE; HALF LIFE TIME; HUMAN; MALE; MEASUREMENT; MIDDLE AGED; MULTIPLE MYELOMA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DRUG MONITORING; METABOLISM; PATHOLOGY; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DRUG MONITORING; FEMALE; HALF-LIFE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; PREDNISONE; PROSPECTIVE STUDIES; PYRAZINES; SENSITIVITY AND SPECIFICITY; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84911976083     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12376     Document Type: Article

References (21)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20.
2. Harousseau JL, Avet-Loiseau H, Attal M, et al. Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: long-Term Analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol 2009;27:5720-6.
3. Moreau P, Attal M, Pégourié B, et al., for the IFM. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood 2011;117:3041-4.
4. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
5. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001;97:2900-2.
6. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003;361:489-91.
7. Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004;126:348-54.
8. Dispenzieri A, Zhang L, Katzmann JA, Snyder M, Blood E, Degoey R. Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008;111:4908-15.
9. Katzmann JA, Clark RJ, Abraham RS. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-44.
10. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73.
11. Yedema C, Kenemans P, Voorhorst F, Bon G, Schijf C, Beex C, Verstraeten A, Hilgers J, Vermorken J. CA 125 half-life in ovarian cancer: a multivariate survival analysis. Br J Cancer 1993;5:1361-7.
12. Hansen CT, Münster AM, Nielsen L, Pedersen P, Abildgaard N. Clinical and preclinical validation of the serum free light chain assay: identification of the critical difference for optimized clinical use. Eur J Haematol 2012;89:458-68.
13. Dispenzieri A. Is early, deep free light chain response really an adverse prognostic factor? Blood 2008;111:2490-1.
14. Uljon SN, Richardson PG, Schur PH, Anderson KC, Tanasijevic MJ, Lindeman NI. Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma. Clin Chim Acta 2011;412:562-8.
15. Pratt G, Mead GP, Godfrey KR, Hu Y, Evans ND, Chappell MJ, Lovell R, Bradwell AR. The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains. Leuk Lymphoma 2006;47:21-8.
16. Van Gysel M, Mariën G, Verhoef G, Delforge M, Bossu X. Free light chain testing in follow-up of multiple meyloma. Clin Chem Lab Med 2006;44:1044-6.
17. Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 2005;36:597-600.
18. Mosbauer U, Ayuk F, Schieder H, Lioznov M, Zander AR. Kr+Âger N. Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation. Haematologica 2007;92:275-6.
19. Robson E, Mead GP, Das M, Cavet J, Liakopoulou E. Free light chain analysis in patients receiving bortezomib. Haematologica 2007;92(Suppl 2):206.
20. Singhal S, Vickrey E, Krishnamurthy J, Singh V, Allen S, Mehta J. The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood 2009;114:38-9.
21. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007;110:827-32.